Gravin Is a Transitory Effector of Polo-like Kinase 1 during Cell Division

Molecular Cell

Volumn 48, Issue 4, 2012, Pages 547-559

  Canton, David A ^a,b   Keene, C Dirk ^a   Swinney, Katie ^b   Langeberg, Lorene K ^a,b   Nguyen, Vivian ^c   Pelletier, Laurence ^c   Pawson, Tony ^c   Wordeman, Linda ^a   Stella, Nephi ^a,b   Scott, John D ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIN B1; G PROTEIN COUPLED RECEPTOR; PHOSPHOLIPID; POLO LIKE KINASE 1; PROTEIN KINASE C;

ARTICLE; CELL DIVISION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FLUORESCENCE IMAGING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MITOSIS; PROTEIN PROTEIN INTERACTION;

A KINASE ANCHOR PROTEINS; ANIMALS; CELL CYCLE PROTEINS; CELL DIVISION; CELL PROLIFERATION; HUMANS; MICE; MITOSIS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED;

EID: 84870393669     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2012.09.002     Document Type: Article

References (42)

1. Ahn N.G. PORE-ing over ERK substrates. Nat. Struct. Mol. Biol. 2009, 16:1004-1005.
2. Akakura S., Huang C., Nelson P.J., Foster B., Gelman I.H. Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Res. 2008, 68:5096-5103.
3. Alexander J., Lim D., Joughin B.A., Hegemann B., Hutchins J.R., Ehrenberger T., Ivins F., Sessa F., Hudecz O., Nigg E.A., et al. Spatial exclusivity combined with positive and negative selection of phosphorylation motifs is the basis for context-dependent mitotic signaling. Sci. Signal. 2011, 4:ra42. 10.1126/scisignal.2001796.
4. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
5. Brennan I.M., Peters U., Kapoor T.M., Straight A.F. Polo-like kinase controls vertebrate spindle elongation and cytokinesis. PLoS ONE 2007, 2:e409. 10.1371/journal.pone.0000409.
6. Burkard M.E., Randall C.L., Larochelle S., Zhang C., Shokat K.M., Fisher R.P., Jallepalli P.V. Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc. Natl. Acad. Sci. USA 2007, 104:4383-4388.
7. Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M., Lowery D.M., Clauser K.R., Zhang C., Shokat K.M., Carr S.A., Yaffe M.B., Jallepalli P.V. Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol. 2009, 7:e1000111. 10.1371/journal.pbio.1000111.
8. Cheng M.W., Wang B.C., Weng Z.Q., Zhu X.W. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta Histochem. 2012, 114:503-509.
9. Christoph D.C., Schuler M. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies. Expert Rev. Anticancer Ther. 2011, 11:1115-1130.
10. Dougherty M.K., Ritt D.A., Zhou M., Specht S.I., Monson D.M., Veenstra T.D., Morrison D.K. KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. Mol. Cell 2009, 34:652-662.
11. Elia A.E., Rellos P., Haire L.F., Chao J.W., Ivins F.J., Hoepker K., Mohammad D., Cantley L.C., Smerdon S.J., Yaffe M.B. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003, 115:83-95.
12. Enserink J.M., Kolodner R.D. An overview of Cdk1-controlled targets and processes. Cell Div. 2010, 5:11.
13. Fabbro D., Cowan-Jacob S.W., Möbitz H., Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol. Biol. 2012, 795:1-34.
14. Gardino A.K., Yaffe M.B. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin. Cell Dev. Biol. 2011, 22:688-695.
15. Gelman I.H. Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis. Genes Cancer 2010, 1:1147-1156.
16. Gordon T., Grove B., Loftus J.C., O'Toole T., McMillan R., Lindstrom J., Ginsberg M.H. Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera. J. Clin. Invest. 1992, 90:992-999.
17. Hoshi N., Langeberg L.K., Gould C.M., Newton A.C., Scott J.D. Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol. Cell 2010, 37:541-550.
18. Jeong K., Jeong J.Y., Lee H.O., Choi E., Lee H. Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos. Dev. Biol. 2010, 345:34-48.
19. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997, 57:5328-5335.
20. Kolodner R.D., Cleveland D.W., Putnam C.D. Cancer. Aneuploidy drives a mutator phenotype in cancer. Science 2011, 333:942-943.
21. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., et al. Long-term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606. German Glioma Network.
22. Lee K.S., Park J.E., Kang Y.H., Zimmerman W., Soung N.K., Seong Y.S., Kwak S.J., Erikson R.L. Mechanisms of mammalian polo-like kinase 1 (Plk1) localization: self- versus non-self-priming. Cell Cycle 2008, 7:141-145.
23. Lin X., Gelman I.H. Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. Cancer Res. 1997, 57:2304-2312.
24. Lin X., Tombler E., Nelson P.J., Ross M., Gelman I.H. A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J. Biol. Chem. 1996, 271:28430-28438.
25. Lowery D.M., Clauser K.R., Hjerrild M., Lim D., Alexander J., Kishi K., Ong S.E., Gammeltoft S., Carr S.A., Yaffe M.B. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J. 2007, 26:2262-2273.
26. Morrison D.K., Davis R.J. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 2003, 19:91-118.
27. Nauert J.B., Klauck T.M., Langeberg L.K., Scott J.D. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr. Biol. 1997, 7:52-62.
28. Nihalani D., Meyer D., Pajni S., Holzman L.B. Mixed lineage kinase-dependent JNK activation is governed by interactions of scaffold protein JIP with MAPK module components. EMBO J. 2001, 20:3447-3458.
29. Obenauer J.C., Cantley L.C., Yaffe M.B. Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 2003, 31:3635-3641.
30. Petronczki M., Glotzer M., Kraut N., Peters J.M. Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Dev. Cell 2007, 12:713-725.
31. Petronczki M., Lénárt P., Peters J.M. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev. Cell 2008, 14:646-659.
32. Scott J.D., Pawson T. Cell signaling in space and time: where proteins come together and when they're apart. Science 2009, 326:1220-1224.
33. Silljé H.H., Nigg E.A. Purification of mitotic spindles from cultured human cells. Methods 2006, 38:25-28.
34. Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., Davis R.J., Scott J.D. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat. Cell Biol. 2010, 12:1242-1249.
35. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6:321-330.
36. Tao J., Wang H.Y., Malbon C.C. Protein kinase A regulates AKAP250 (gravin) scaffold binding to the beta2-adrenergic receptor. EMBO J. 2003, 22:6419-6429.
37. Tsujimoto K., Ono T., Sato M., Nishida T., Oguma T., Tadakuma T. Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J. Biol. Chem. 2005, 280:27638-27644.
38. Van Meir E.G., Hadjipanayis C.G., Norden A.D., Shu H.K., Wen P.Y., Olson J.J. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin. 2010, 60:166-193.
39. Vermeulen K., Van Bockstaele D.R., Berneman Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003, 36:131-149.
40. Willoughby D., Wong W., Schaack J., Scott J.D., Cooper D.M. An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. EMBO J. 2006, 25:2051-2061.
41. Xia W., Unger P., Miller L., Nelson J., Gelman I.H. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res. 2001, 61:5644-5651.
42. Zhu Y., Hollmén J., Räty R., Aalto Y., Nagy B., Elonen E., Kere J., Mannila H., Franssila K., Knuutila S. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br. J. Haematol. 2002, 119:905-915.